Notably, treatment with an ATR inhibitor abolished DDUP-induced DNA damage repair and protection against apoptosis, leading to the development of CDDP-resistant ovarian cancer cells that were more vulnerable to platinum-based chemotherapeutic agents [39, 40]. Here, ATR is linked to ovarian carcinoma.